Login to Your Account

Lung shot: Merck's results 'raise bar' for BMS, others scrambling for share of IO

By Randy Osborne
Staff Writer

Thursday, June 16, 2016

With immuno-oncology (IO) revving faster than even optimists predicted and chemotherapy for NSCLC fated to become an image in the rearview mirror, research continues to grope for the just-right levels of programmed death-ligand 1 expression that lets programmed cell death-1 inhibitors work best.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription